T cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy has generated a great amount of interest and have encouraged investors to support development in the field of adoptive cellular immunotherapy. Over the past couple of years, there has been rapid progress in the field. Researchers are refining the safety and efficacy profiles of CAR T cells with new concepts and technologies. These will be therapies that will address current challenges through mechanisms of superior efficacy, safety and delivery.